-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV-2-IN-9
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1453052-57-7.gif)
| Category | SARS-CoV |
| CAS | 1453052-57-7 |
| Description | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor. SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease. |
Product Information
| Synonyms | 6-[4-(3,4-dichlorophenyl)piperazin-1-yl]carbonyl-1~{H}-pyrimidine-2,4-dione|YD1|SARS-CoV-2-IN-9|ZINC95374297|CS-0256169|6-{[4-(3,4-dichlorophenyl)-1-piperazinyl]carbonyl}-2,4(1H,3H)-pyrimidinedione |
| Molecular Weight | 369.2 |
| Molecular Formula | C15H14Cl2N4O3 |
| Canonical SMILES | C1CN(CCN1C2=CC(=C(C=C2)Cl)Cl)C(=O)C3=CC(=O)NC(=O)N3 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 575 |
| Exact Mass | 368.0442957 |
| Target | SARS-CoV |
| XLogP3-AA | 1.5 |
